Table 2.

Numbers and Rates of Inappropriate Acute Viral Hepatitis Serology Testing Before and After Interventions

Test
Data Collection PeriodVariableAnti-HAV IgM TestAnti-HBc IgM
PreinterventionTotal eligible tests analyzed, n2,4394,462
ALT or AST ≥250 U/L, n (%)228 (9.3)280 (6.3)
ALT or AST <250 U/L, n (%)2,211 (90.7)4,182 (93.7)
Rate of inappropriate testing, %90.793.7
Post first interventionTotal tests ordered, n1,4951,830
Total eligible tests analyzed, n1,3111,573
ALT or AST ≥250 U/L, n (%)255 (19.5)266 (16.9)
ALT or AST <250 U/L, n (%) or serologic evidence of immunity1,056 (80.5)1,307 (83.1)
Rate of inappropriate testing, %80.583.1
P value<0.0001<0.0001
Post second interventionTotal tests ordered, n1,1591,437
Total eligible tests analyzed, n9981,184
ALT or AST ≥250 U/L, n (%)199 (19.9)200 (16.9)
ALT or AST <250 U/L, n (%) or serologic evidence of immunity799 (80.1)984 (83.1)
Rate of inappropriate testing, %80.183.1
P value<0.0001<0.0001
  • Notes: Serologic evidence of immunity to HAV and HBV is defined as the presence a positive anti-HAV total (>6 months) and positive anti-HBs (>6 months), respectively. Eligible tests are less than the total tests, as tests without AST or ALT values within 30 days of ordering the serology were excluded. P value is 2-sided comparing the preintervention and postintervention appropriate and inappropriate proportions using Fisher exact test.

  • ALT, alanine aminotransferase; anti-HAV IgM, hepatitis A virus immunoglobulin M antibody; anti-HAV total, hepatitis A virus total antibody; anti-HBc IgM, hepatitis B virus core immunoglobulin M antibody; anti-HBs, hepatitis B virus surface antibody; HAV, hepatitis A virus; HBV, hepatitis B virus; AST, aspartate aminotransferase.